LexaGene Holdings Inc (OTCQB:LXXGF) (CVE:LXG) (FRA:5XS2) has announced a strategic relationship with intellectual property (IP) law firm Wolf Greenfield as it continues to expand its patent portfolio.
The company said adding Wolf Greenfield to its representation portfolio also strengthened its positioning towards possibly listing its common shares on the Nasdaq Capital Market.
READ: LexaGene Holdings unveils the second iteration of its MiQLab Bacterial and AMR Panel, capable of more robust pathogen screening
Wolf Greenfield has over 150 legal professionals based in Boston and New York, specializing in patents, licensing and royalty transactions, post-grant proceedings, and trademark and copyrights.
“As LexaGene continues to grow, it’s important to not only protect but nurture and grow the intellectual property assets of the company,” CEO and founder Dr Jack Regan said in a statement.
“Combining the strengths of Wolf Greenfield for IP law and licensing, along with Latham & Watkins for securities law, gives us the capabilities of two of the most respected law firms in the US in their respective fields, as we continue to execute on our growth objectives.”
The company also announced that Dr Regan will be speaking at the “Access to Giving” investor conference on Thursday, July 15.
Access to Giving is a first-of-its-kind, virtual investor conference, where companies from microcap up to mega-cap will have the opportunity to present their company’s vision and participate in meetings with qualified investors, all to benefit a range of charities.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing, and biodefense.
Contact the author at stephen.gunnion@proactiveinvestors.com